NSE ScannerPharmaceuticals · Pharmaceuticals: Other · NSE: AUROPHARMA · data 2026-10-30
Aurobindo Pharma Ltd
In plain words
Price: 3.4% below its 52-week high of ₹1,740.
Delivery: 54.1% of traded shares were kept for delivery over the last 10 sessions, against 51.3% over the last 60.
Latest results: a net profit of ₹1,033 cr for the quarter ended Jun 2026 (+25.2% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹34,935 cr |
| Net profit (last 12 months) | ₹3,713 cr |
| Sales growth, 3 years (yearly) | 10.7% |
| Profit growth, 3 years (yearly) | 22.1% |
Latest results in brief (Q1 FY27)
AUROPHARMA Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹9,150.35 crore, up 16.3% YoY and up 3.4% QoQ.
Net profit was ₹1,032.56 crore, up 25.2% YoY and up 12.1% QoQ.
Operating margin was 20.6% (20.4% a year ago).
EPS was ₹17.86, up 25.8% YoY and up 12.6% QoQ.
AUROPHARMA के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹9,150.35 करोड़; पिछले साल की तुलना में 16.3% की बढ़त, पिछली तिमाही की तुलना में 3.4% की बढ़त।
शुद्ध मुनाफ़ा: ₹1,032.56 करोड़; पिछले साल की तुलना में 25.2% की बढ़त, पिछली तिमाही की तुलना में 12.1% की बढ़त।
ऑपरेटिंग मार्जिन: 20.6% (एक साल पहले 20.4%)।
EPS: ₹17.86; पिछले साल की तुलना में 25.8% की बढ़त, पिछली तिमाही की तुलना में 12.6% की बढ़त।
AUROPHARMAના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹9,150.35 કરોડ; ગયા વર્ષની સરખામણીએ 16.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 3.4% વધારો.
ચોખ્ખો નફો: ₹1,032.56 કરોડ; ગયા વર્ષની સરખામણીએ 25.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 12.1% વધારો.
ઓપરેટિંગ માર્જિન: 20.6% (એક વર્ષ પહેલાં 20.4%).
EPS: ₹17.86; ગયા વર્ષની સરખામણીએ 25.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 12.6% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
35/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 54.4% over the last 20 sessions vs 49.8% in the 40 before (1.09x); shares delivered per day 1.03x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 39 schemes hold it, about ₹4,030 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 63/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 5 Aug 26Results Q1 FY27 results: profit +25.2% YoY +0.2% next session
- 21 May 26Results Q4 FY26 results: profit +2.0% YoY -3.6% next session
- 9 Feb 26Results Q3 FY26 results: profit +6.5% YoY -5.6% next session
- 5 Nov 25Results Q2 FY26 results: profit +3.8% YoY -0.7% next session
- 8 Aug 25Dividend Dividend ₹4 (ex-date) -1.6% next session
- 4 Aug 25Results Q1 FY26 results: profit −10.3% YoY 0.0% next session
- 27 May 25Results Q4 FY25 results: profit −0.6% YoY -2.8% next session
- 6 Feb 25Results Q3 FY25 results: profit −8.7% YoY 0.0% next session
- 9 Nov 24Results Q2 FY25 results: profit +8.0% YoY -2.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹9,150 cr | ₹1,033 cr | +25.2% | 20.6% | 17.86 |
| Mar 2026 | ₹8,853 cr | ₹921 cr | +2.0% | 19.8% | 15.86 |
| Dec 2025 | ₹8,646 cr | ₹910 cr | +6.5% | 20.5% | 15.67 |
| Sept 2025 | ₹8,286 cr | ₹848 cr | +3.8% | 20.3% | 14.61 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 51.88% | 51.88% | 51.82% | 51.82% |
| Foreign institutions (FII) | 17.41% | 16.38% | 15.24% | 13.94% |
| Domestic institutions (DII) | 24.42% | 25.10% | 25.87% | 27.68% |
| Mutual funds | 16.31% | 16.71% | 17.79% | 19.52% |
| Retail investors | 4.69% | 5.03% | 5.35% | 5.03% |
| Number of shareholders | 2,33,737 | 2,39,073 | 2,41,298 | 2,36,859 |
Common questions
What was Aurobindo Pharma Ltd's latest quarterly profit?
Aurobindo Pharma Ltd reported a net profit of ₹1,033 cr for the quarter ended Jun 2026 (+25.2% on the same quarter a year earlier), on revenue of ₹9,150 cr.
How much do promoters hold in Aurobindo Pharma Ltd?
Promoters held 51.88% of Aurobindo Pharma Ltd at the end of Sept 2026, with 11.99% of promoter shares pledged.
Is Aurobindo Pharma Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.21.
What is Aurobindo Pharma Ltd's P/E ratio?
About 26.3, based on the last 12 months' earnings and a price of ₹1,681.4 (data 2026-10-30).
What is the 52-week high and low of Aurobindo Pharma Ltd?
The 52-week high is ₹1,740 and the 52-week low is ₹1,106.
Mutual funds holding Aurobindo Pharma Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 39 schemes holding about ₹4,030 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Large and Midcap Fund | SBI Mutual Fund | 1.94% | ₹786 cr |
| SBI Flexicap Fund | SBI Mutual Fund | 3.03% | ₹670 cr |
| SBI Midcap Fund | SBI Mutual Fund | 2.18% | ₹508 cr |
| SBI ELSS Tax Saver Fund | SBI Mutual Fund | 0.84% | ₹252 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 3.42% | ₹201 cr |
| SBI Dividend Yield Fund | SBI Mutual Fund | 2.49% | ₹201 cr |
| SBI MNC Fund | SBI Mutual Fund | 2.62% | ₹167 cr |
| SBI Multi Asset Allocation Fund | SBI Mutual Fund | 0.77% | ₹162 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.65% | ₹151 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 3.78% | ₹132 cr |
| Nippon India Vision Large & Mid Cap Fund | Nippon India Mutual Fund | 1.57% | ₹116 cr |
| SBI Equity Savings Fund | SBI Mutual Fund | 1.95% | ₹106 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 4.69% | ₹81 cr |
| SBI Quant Fund | SBI Mutual Fund | 2.44% | ₹63 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 4.52% | ₹49 cr |
Similar companies
Cipla Ltd (CIPLA) · Lupin Limited (LUPIN) · Granules India Limited (GRANULES) · Sudeep Pharma Limited (SUDEEPPHRM) · Amrutanjan Health Care Limited (AMRUTANJAN)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AUROPHARMA in NSE Scanner →